Which drug is identified as the second generation P2Y12 antagonist?

The second-generation P2Y12 antagonist is Clopidogrel. This class of drugs is used primarily to prevent platelet aggregation and reduce the risk of thrombotic cardiovascular events. Clopidogrel is more effective than its predecessor, Ticlopidine, because it has a better safety profile and fewer side effects. It is an important part of dual antiplatelet therapy, especially after myocardial infarction or stenting procedures, as it irreversibly inhibits the P2Y12 receptor on platelets.

Prasugrel, although also a P2Y12 antagonist, is considered a third-generation agent, making Clopidogrel the correct identification for the second generation. Aspirin is an antiplatelet medication but works through a different mechanism, primarily by irreversibly inhibiting cyclooxygenase and thus preventing thromboxane A2 formation, which further differentiates it from P2Y12 antagonists.